Spyre Therapeutics (SYRE) Receivables - Accured (2019 - 2026)
Spyre Therapeutics posted quarterly Receivables - Accured of $4.6 million for Q1 2026, up 35.29% year-on-year from $3.4 million in Q1 2025, and up 2.22% on a QoQ basis from $4.5 million in Q4 2025.
Spyre Therapeutics (SYRE) has 8 years of Receivables - Accured data on file, last reported at $4.6 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Accured rose 35.29% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (up 35.29% YoY), and the FY2025 full-year result was $4.5 million, up 32.35% from the prior year.
- Receivables - Accured for Q1 2026 stood at $4.6 million, up from $4.5 million in the prior quarter.
- Across five years, Receivables - Accured topped out at $4.6 million in Q1 2026 and bottomed at $100000.0 in Q4 2022.
- The 5-year median for Receivables - Accured is $1.8 million (2024), against an average of $2.1 million.
- The widest annual swing landed in 2022, when Receivables - Accured changed 0.0%; it then soared 1700.0% in 2024.
- A 5-year view of Receivables - Accured shows it stood at $100000.0 in 2022, then soared by 800.0% to $900000.0 in 2023, then jumped by 277.78% to $3.4 million in 2024, then soared by 32.35% to $4.5 million in 2025, then advanced by 2.22% to $4.6 million in 2026.
- The last three Receivables - Accured figures came in at $4.6 million (Q1 2026), $4.5 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | 4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.60 Mn |
| Mar 31, 2026 | 4.60 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 3.60 Mn |
| Sep 30, 2025 | 3.60 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 3.40 Mn |
| Mar 31, 2025 | 3.40 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |
| Sep 30, 2023 | 400,000.00 |
| Sep 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 100,000.00 |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 100,000.00 |
| Dec 31, 2021 | 100,000.00 |
| Sep 30, 2021 | 100,000.00 |
| Sep 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Mar 31, 2021 | 200,000.00 |
| Mar 31, 2021 | 200,000.00 |
| Dec 31, 2020 | 200,000.00 |
| Dec 31, 2020 | 200,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 100,000.00 |
| Mar 31, 2020 | 200,000.00 |
| Mar 31, 2020 | 200,000.00 |
| Dec 31, 2019 | 300,000.00 |
| Dec 31, 2019 | 300,000.00 |